A Phase 2, Multi-center, Randomized, Double-masked, Placebo (Vehicle)-Controlled Clinical Study With an Open Label Comparator Arm to Assess the Efficacy, Safety and Tolerability of Topical CyclASol® for Treatment of Dry Eye Disease
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Novaliq GmbH
- 入组人数
- 207
- 试验地点
- 1
- 主要终点
- Change From Baseline (Visit 1) in Total Corneal Fluorescein Staining at 113 Days
研究概览
简要总结
The objective of this study was to compare the safety, efficacy, and tolerability of two different dose levels of CyclASol Ophthalmic Solutions to placebo (vehicle) and Restasis for the treatment of the signs and symptoms of Dry Eye Disease (DED).
详细描述
This phase 2 study explored the safety, efficacy and tolerability of two CyclASol concentrations as one drop twice daily versus vehicle (placebo). In addition to the masked vehicle control arm, an open-label comparator arm consisting of Restasis was included.
The study explored a range of signs and symptoms of DED to gain an understanding of the possible treatment effects in comparison to vehicle and estimation of effect sizes. In line with current treatment guidelines, the proposed phase 2 population consisted of patients suffering from moderate to severe DED.
The primary treatment comparisons in this study were between the two CyclASol concentrations versus vehicle for the sign variable total corneal fluorescein staining and the symptom variable dryness severity visual analogue scale at day 113. All other comparisons between treatments groups were considered secondary analyses.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed Informed Consent Form and HIPAA (Health Insurance Portability and Accountability Act ) document
- •Patient-reported history of dry eye in both eyes
- •Current use of over-the-counter and/or prescription eye drops for dry eye symptoms
- •Ability and willingness to follow instructions, including participation in all study assessments and visits
排除标准
- •Women who are pregnant, nursing or planning a pregnancy
- •Unwillingness to submit a blood pregnancy test at screening and at the last visit (or early termination visit) if of childbearing potential, or unwillingness to use acceptable means of birth control
- •Clinically significant slit-lamp findings or abnormal lid anatomy at screening
- •DED secondary to scarring or ocular or periocular malignancy
- •History of herpetic keratitis
- •Active ocular allergies or ocular allergies that are expected to be active during the study period
- •Ongoing ocular or systemic infection at screening or baseline
- •Wear of contact lenses within 3 months prior to screening or anticipated use of contact lenses during the study
- •History of no response to previous topical Cyclosporine A and/or use of topical Cyclosporine A within 6 months prior to screening
- •Intra-ocular surgery or ocular laser surgery within the previous 6 months, or have any planned ocular and/or lid surgeries over the study period
- •Presence of an uncontrolled systemic disease
- •Presence of a known allergy and/or sensitivity to the study drug or its components
研究组 & 干预措施
CyclASol Ophthalmic Solution 1
Cyclosporine A solution (dose-level 1) in vehicle
干预措施: Cyclosporine A (Drug)
CyclASol Ophthalmic Solution 2
Cyclosporine A solution (dose-level 2) in vehicle
干预措施: Cyclosporine A (Drug)
Placebo Ophthalmic Solution
Vehicle only
干预措施: Placebo (Drug)
Restasis
Cyclosporine A 0.05% ophthalmic emulsion
干预措施: Cyclosporine A (Drug)
结局指标
主要结局
Change From Baseline (Visit 1) in Total Corneal Fluorescein Staining at 113 Days
时间窗: Baseline to 113 Days
The primary analysis and objective of the study was to compare the two CyclASol groups versus vehicle (all blinded treatment arms) for one sign and one symptom endpoint. The open label active comparator arm was not included in the primary analysis to reduce the number of comparisons. The sign endpoint was the change from baseline in total corneal fluorescein staining at day 113. The cornea is divided into five regions: central, superior, inferior, nasal and temporal. Each region is graded from 0-3 based on the National Eye Institute scale, where 0 indicates no staining and 3 maximal staining. The total score is the sum of all these regions. The maximum score for each eye is 15.
Change From Baseline (Visit 1) in Dryness Severity Visual Analog Scale (VAS) at 113 Days
时间窗: Baseline to 113 Days
The primary analysis and objective of the study was to compare the the two CyclASol groups versus vehicle (all blinded treatment arms) for one sign and one symptom endpoint. The open label active comparator arm was not included in the primary analysis to reduce the number of comparisons. Furthermore, the open label character could have had an impact on patient reported outcomes. The symptom endpoint was the change from baseline in severity of dryness VAS at Day 113. Dryness severity was rated from 0 to 100%, where 0% corresponds to "no dryness" and 100% corresponds to "maximum dryness".
次要结局
未报告次要终点